瑞舒伐他汀联合环磷腺苷葡胺治疗急性心肌梗死对血清VEGF-B和GDF-15水平的影响  

Effect of rosuvastatin combined with cyclophosphine adenosine glucosamine on acute myocardial infarction

作　　者：刘少云[1] 崔松[1] 于娜 吴秀琴 齐敏 LIU Shaoyun;CUI Song;YU Na;WU Xiuqin;QI Min(Department of Cardiology,General Hospital of North China Petroleum Administration,Hebei Province,Renqiu 062550,China)

机构地区：[1]华北石油管理局总医院心内科

出　　处：《疑难病杂志》2019年第12期1195-1199,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：河北省中医药管理局科研计划项目(2019469);华北油田矿区医疗卫生临床调查相关研究(2016-HB-G0401)

摘　　要：目的观察瑞舒伐他汀联合环磷腺苷葡胺治疗急性心肌梗死对血清血管内皮生长因子B(VEGF-B)和生长分化因子15(GDF-15)水平的影响。方法收集2016年6月-2019年2月华北石油管理局总医院心脏科收治急性心肌梗死患者102例,按随机数字表法分为2组各51例,单药组予环磷腺苷葡胺注射液,联合组在单药组基础上口服瑞舒伐他汀钙片,治疗28 d后,比较2组患者治疗效果,检测血清VEGF-B和GDF-15水平、心肌梗死标志物等指标、心功能参数变化,记录不良反应发生情况。结果治疗后,联合组总有效率为96.1%,高于对照组的82.4%(χ^2=4.990,P=0.025),与治疗前比较,治疗后2组血清VEGF-B水平上升,GDF-15水平下降,且联合组升高/降低幅度大于单药组(t/P=2.004/0.048、4.849/0.000);而肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnI)、肌红蛋白(Mb)水平均低于单药组(t/P=7.570/0.000、4.800/0.000、3.904/0.000),脑钠肽(NT-proBNP)、C-反应蛋白(CRP)、髓过氧化物酶(MPO)、同型半胱氨酸(Hcy)水平亦低于单药组(t/P=22.571/0.000、8.454/0.000、25.349/0.000、3.935/0.000);CO、SV、LVEF指标明显高于单药组(t/P=5.382/0.000、4.362/0.000、5.182/0.000)。联合组不良反应率为11.8%,高于对照组的5.9%,但差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合环磷腺苷葡胺可提高急性心肌梗死治疗效果,提高血清VEGF-B水平,降低GDF-15水平,改善心功能,且无明显不良反应。Objective To observe the effects of rosuvastatin combined with cyclophosphine adenosine glucosamine on the levels of serum vascular endothelial growth factor B(VEGF-B) and growth differentiation factor 15(GDF-15) in patients with acute myocardial infarction.Methods A total of 102 patients with acute myocardial infarction were collected from the Department of Cardiology of North China Petroleum Administration General Hospital from June 2016 to February 2019.According to the random number table method,51 cases were divided into 2 groups.The single drug group was given cyclophosphine adenosine glucosamine injection.The combination group took rosuvastatin calcium tablets orally on the basis of the single drug group.After 28 days of treatment,the treatment effects of the two groups were compared.Changes of serum VEGF-B and GDF 15 levels,markers of myocardial infarction,changes in cardiac function parameters,and the occurrence of adverse reactions were recorded.Results After treatment,the total effective rate in the combined group was 96.1%,which was higher than the control groups 82.4%(χ^2=4.990,P=0.025).Compared with before treatment,serum VEGF-B levels increased and GDF-15 levels decreased in the two groups after treatment,and the increase/decrease in the combined group was greater than that in the single drug group(t/P=2.004/0.048,t/P=4.849/0.000).The levels of creatine kinase isoenzyme(CK-MB),troponin(cTnI),and myoglobin(Mb) were lower than those of the single drug group(t/P=7.570/0.000,t/P=4.800/0.000,t/P=3.904/0.000),brain natriuretic peptide(NT-proBNP),C-reactive protein(CRP),myeloperoxidase(MPO),and homocysteine(Hey) levels were also lower than those of the single drug group(t/P=22.571/0.000,t/P=8.454/0.000,t/P=25.349/0.000,t/P=3.935/0.000).The CO,SV,and LVEF indicators were significantly higher than those of the single-agent group(t/P=5.382/0.000,t/P=4.362/0.000,t/P=5.182/0.000).The adverse reaction rate in the combined group was 11.8%,which was higher than the 5.9% in the control group,but the difference wa

关 键 词：瑞舒伐他汀 环磷腺苷葡胺 心肌梗死 急性 血管内皮生长因子B 生长分化因子15 

分 类 号：R54[医药卫生—心血管疾病]